Generics of Lipitor, Plavix Coming This Year
Versions of those drugs will be cheaper, but overall Rx costs will rise.

Generic copies of the two best-selling drugs, Lipitor and Plavix, will reach pharmacy shelves this year, providing less-expensive alternatives to lowering cholesterol and preventing blood clots.
The drugs are among six blockbusters that will lose patent protection this year. The others are Levaquin, an antibiotic; Taxotere, a cancer drug; Concerta, for attention deficit hyperactivity disorder; and Zyprexa, for treatment of schizophrenia.
Lipitor and Plavix account for $13.1 billion in combined annual sales.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The availability of generic equivalents will help users and employers save money. In 2009, the average retail price was 75% lower than the price of name-brand drugs. In addition to the lower cost, many prescription drug plans require lower copays for generics than for brand-name medications.
Generic drugs claimed about 75% of the market in 2009. The share is expected to reach 85% by 2014.
Despite generic availability of some monster drugs, you should expect a 5% increase in overall drug costs in 2011, the third straight year of single-digit increases. Part of the reason is that generics will be phased in. The Lipitor equivalent, for example, won’t be available until late fall.
The generics shouldn’t have much impact on drug company stock prices when they hit the market. The coming end of patent protection has been known well in advance, so any adjustment is likely already factored into share prices.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

-
Rally Fades on Mixed AI Revolution News: Stock Market Today
All three main U.S. equity indexes opened higher but closed lower as a seven-session winning streak for the S&P 500 came to an end.
-
Stretch Your Holiday Shopping Budget Further with These Under-$50 Gifts That Don't Feel Cheap
Amazon October Prime Day is the perfect chance to nab some under-$50 gifts that feel more expensive than they are (because normally they would be).
-
Apple Readies for AI Upgrade with New iPhones
The Kiplinger Letter The tech giant has stumbled when it comes to artificial intelligence, but a new batch of iPhones will help it make headway.
-
Japan Enters a New Era of Risk and Reform
The Kiplinger Letter Japan has entered a pivotal moment in its economic history, undertaking ambitious policy and structural reforms to escape from decades of stagnation.
-
How Consumers Are Tinkering with Cutting-Edge AI
The Kiplinger Letter Companies launching artificial intelligence tools are jostling for consumer attention. Some products are already building a deep connection with users.
-
After Years of Stagnant Growth, Hope Emerges for EU Economy
The Kiplinger Letter Can a German fiscal push outweigh French political peril?
-
Small Businesses Are Racing to Use AI
The Kiplinger Letter Spurred on by competitive pressures, small businesses are racing to adopt AI. A recent snapshot shows the technology’s day-to-day uses.
-
How AI Puts Company Data at Risk
The Kiplinger Letter Cybersecurity professionals are racing to ward off AI threats while also using AI tools to shore up defenses.
-
AI Start-ups Are Rolling in Cash
The Kiplinger Letter Investors are plowing record sums of money into artificial intelligence start-ups. Even as sales grow swiftly, losses are piling up for AI firms.
-
What is AI Worth to the Economy?
The Letter Spending on AI is already boosting GDP, but will the massive outlays being poured into the technology deliver faster economic growth in the long run?